Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Argenx Se (ARGX) Research & Development (2016 - 2026)

Argenx Se filings provide 11 years of Research & Development readings, the most recent being -$443.0 million for Q1 2026.

  • On a quarterly basis, Research & Development fell 42.44% to -$443.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$1.5 billion, a 39.9% decrease, with the full-year FY2025 number at $1.4 billion, up 38.71% from a year prior.
  • Research & Development hit -$443.0 million in Q1 2026 for Argenx Se, down from -$371.7 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of -$126.9 million in Q2 2022 to a low of -$443.0 million in Q1 2026.
  • Median Research & Development over the past 5 years was -$235.9 million (2024), compared with a mean of -$253.7 million.
  • The widest YoY moves for Research & Development: up 18.98% in 2023, down 107.29% in 2023.
  • Argenx Se's Research & Development stood at -$147.8 million in 2022, then tumbled by 107.29% to -$306.4 million in 2023, then grew by 2.98% to -$297.2 million in 2024, then dropped by 25.06% to -$371.7 million in 2025, then fell by 19.18% to -$443.0 million in 2026.
  • The last three reported values for Research & Development were -$443.0 million (Q1 2026), -$371.7 million (Q4 2025), and -$355.7 million (Q3 2025) per Business Quant data.